Navigation Links
Novavax Announces Top Line Results of Phase IIa Clinical Trial for Its Seasonal Influenza VLP (Trivalent) Vaccine Candidate
Date:12/11/2008

thin 12 weeks of identification of the Centers for Disease Control and Prevention ("CDC") released seasonal strains, or approximately half the time required to manufacture egg-based vaccines. The ability to rapidly respond to the identification of annual seasonal strains may be important in providing timely vaccine in advance of annual physicals for children before the school year.

Seasonal Influenza

The majority of individuals with influenza recover in less than two weeks; however, some may develop life-threatening complications such as pneumonia. In addition, influenza exacerbates the symptoms of chronic health conditions such as diabetes, asthma and congestive heart failure. The most severe disease occurs in infants and young children and adults older than 65 years of age. The CDC reports that 15 to 60 million people in the U.S. contract influenza each year leading to over 200,000 hospitalizations and 36,000 deaths. The Advisory Committee on Immunization Practices ("ACIP"), which has been expanding recommendations for seasonal influenza vaccination for the last several years, currently recommends seasonal influenza vaccination for children 6 months through 18 years of age, pregnant women, adults over 50 years of age, and individuals of any age with chronic health conditions or who are at high risk of influenza disease. Based on the expanding recommendation of vaccination to new age groups, the growing worldwide population to be vaccinated, and the need of an improved influenza vaccine for the elderly, global market projections of seasonal influenza are estimated to increase from $2.8 billion in 2007 to $6.5 billion by 2013.

About Novavax

Novavax, Inc. is a clinical stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP
'/>"/>

SOURCE Novavax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Novavax CEO to Present at ACUMENBioFins 9th Annual Healthcare Conference
2. Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs
3. GE Healthcare and Novavax Establish Collaboration To Develop and Market Pandemic Influenza Solution
4. Novavax Announces Preclinical Results for Seasonal Influenza Vaccine Program
5. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
6. Novavax Reports Fourth Quarter and 2007 Year-End Financial Results
7. Novavax Reports Positive Results from Preclinical Studies of its VLP-based Trivalent Seasonal Influenza Vaccine Candidate
8. Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial
9. Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development
10. Novavax to Present Phase I/IIa Trial Data Results in an Investor Conference Call on August 26, 2008
11. Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 20, 2014 Valeritas, Inc., a leader in ... with Type 2 diabetes, announced today that it has ... The award was presented October 16 th at ... Ohio . The Cardinal Health ... variety of metrics specifically targeted at the importance of ...
(Date:10/20/2014)... , Oct. 20, 2014 Pharmaceutic Labs ... facility in Albany, NY for ... The company meets and/or exceeds the FDA standards for ... 21 CFR Part 211. The 10,000 ... highest levels of quality assurance and quality control. The ...
(Date:10/19/2014)... , Oct. 20, 2014 CTI BioPharma Corp. ... will report its third quarter 2014 financial results on ... U.S. financial markets. Following the announcement, members of the ... discuss the results and provide a general corporate update ... the event can be obtained as follows: ...
Breaking Medicine Technology:Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 2
... Anlit Advanced Nutrition Supplements , an ... for children, will present new and innovative products at ... 2012 in Geneva, Switzerland. Anlit will showcase new ... at Stand 3500. The company will present, among others, ...
... 2012  Luminex Corporation (NASDAQ: LMNX ) today announced ...  Financial and operating highlights include the following: , ... increase over the first quarter of 2011 , First ... over the first quarter of 2011 , First quarter ...
Cached Medicine Technology:Anlit to Present New Dietary Supplements for Children at Vitafoods Europe 2012 2Luminex Corporation Reports First Quarter 2012 Results 2Luminex Corporation Reports First Quarter 2012 Results 3Luminex Corporation Reports First Quarter 2012 Results 4Luminex Corporation Reports First Quarter 2012 Results 5Luminex Corporation Reports First Quarter 2012 Results 6Luminex Corporation Reports First Quarter 2012 Results 7Luminex Corporation Reports First Quarter 2012 Results 8
(Date:10/20/2014)... York, NY (PRWEB) October 20, 2014 ... based non-profit organization that helps New Yorkers living ... positive changes toward health, housing, recovery and self-sufficiency. ... have transformed the local community through their tireless ... Director, Marc Shapses , has been selected ...
(Date:10/20/2014)... 2014 hc1.com today announced the ... solution that enables healthcare organizations of all sizes ... customer relationship management (“CRM”) solution. , Designed from ... of the healthcare industry, the hc1 Healthcare Relationship ... patients by combining healthcare CRM, HIPAA-compliant collaboration, and ...
(Date:10/20/2014)... Kennewick, WA (PRWEB) October 20, 2014 ... new workflow management software application. The new module ... ensure patients receive full life-cycle quality care. , This ... to others within their practice, attach a to-do item ... see fit, and even set up reoccurring reminders for ...
(Date:10/20/2014)... 20, 2014 Myoderm ... Assistant Director of their CentralSource service. ... the innovative turnkey drug sourcing, distribution, and management ... over 12 years of industry experience, in both ... the peak of their international success to help ...
(Date:10/20/2014)... October 20, 2014 Based on ... the only imaging assays capable of determining DNA ... test.  With these three dimensions of high-resolution data, ... detect the widest range of disease-causing genetic rearrangements, ... by other genomic tools, including today’s advanced sequencing ...
Breaking Medicine News(10 mins):Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:My Clients Plus Announces New Workflow Management Software 2Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3
... ... ... ... ...
... ... ... ... ...
... Initiating antiretroviral therapy (ART) during tuberculosis therapy significantly reduced ... trial of 642 patients co-infected with HIV and tuberculosis. ... of TB and HIV services, lays to rest the ... or after TB treatment. Findings are published in the ...
... February 2010 - The 1994 genocide in Rwanda resulted in ... the course of about 100 days. Although the exact ... 20% of the country,s entire population was murdered. There ... the survivors developed posttraumatic stress disorder, or PTSD, an anxiety ...
... evidence that "safe" plastics are not as safe as once ... ( http://www.fasebj.org ) suggests that exposure to Bisphenol A ... permanent reproduction problems for female offspring. BPA, a common component ... estrogen that is ubiquitous in the environment. ...
... THURSDAY, Feb. 25 (HealthDay News) -- Competition in the health ... report that looked at data from 43 states and 313 ... largest insurers had a combined market share of 70 percent ... type of market situation. , Among the other findings: ...
Cached Medicine News:Health News:DSM Personalized Nutrition Webinar Explores Benefits of Nutrition for Employee Health 2Health News:DSM Personalized Nutrition Webinar Explores Benefits of Nutrition for Employee Health 3Health News:DSM Personalized Nutrition Webinar Explores Benefits of Nutrition for Employee Health 4Health News:DSM Personalized Nutrition Webinar Explores Benefits of Nutrition for Employee Health 5Health News:MedTrust Online Brings MICROMEDEX(R) DRUGDEX(R) From Thomson Reuters to Over 7,000 Online Oncologists 2Health News:MedTrust Online Brings MICROMEDEX(R) DRUGDEX(R) From Thomson Reuters to Over 7,000 Online Oncologists 3Health News:MedTrust Online Brings MICROMEDEX(R) DRUGDEX(R) From Thomson Reuters to Over 7,000 Online Oncologists 4Health News:MedTrust Online Brings MICROMEDEX(R) DRUGDEX(R) From Thomson Reuters to Over 7,000 Online Oncologists 5Health News:Combined drug therapy to treat TB and HIV significantly improves survival 2Health News:Rwandan genocide survivors provide new insights into resilience and PTSD 2Health News:Why BPA leached from 'safe' plastics may damage health of female offspring 2Health News:Health Insurance Competition Vanishing: Study 2
A lytic reagent manufactured for the simultaneous quantitative determinations of hemoglobin and white blood cells. Streck-Lysing Agent III is for use on the Abbott CELL-DYN® 1400 and 1600. The sh...
Streck-Diluent CD is a balanced electrolyte solution manufactured specifically for use as a diluent for blood cell counting and sizing on the Abbott CELL-DYN® 1800....
Streck-Detergent IIIA is a balanced electrolyte solution for use as a rinsing and hemoglobin blanking diluent. It is manufactured specifically for use on the Abbott CELL-DYN® 1700 and 1800. The s...
... hematology control for the Abbott CELL-DYN 3000, ... for the five-part white cell differential, as ... CELL-DYN 1600 and 1700. Open-vial stability is ... days. Para 12 Plus is packaged in ...
Medicine Products: